Lipella Pharmaceuticals, Inc. · OTC:LIPO
Lipella Pharmaceuticals — Investor Presentation (July 2024)
22 slides from Lipella Pharmaceuticals's investor presentation, July 2024
Slide 1: A Clinical Stage Biotechnology Company Addressing Serious Diseases
A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need NASDAQ:LIPO lipellapharmaceuticals.com
Slide 2: Disclaimers
NASDAQ:LIPO Disclaimers The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (“Lipella,” the “Company,” “we,” “us,” or “our”) during this informational meeting. We request that you keep any information we provide at this meeting con
Slide 3: Mission
NASDAQ:LIPO Mission Lipella is dedicated to improving the quality of life for patients living with serious diseases where no approved drug therapy exists. A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need 3
Slide 4: Business Growth Strategy
NASDAQ:LIPO Business Why rare and orphan drugs? Growth • Lipella can be first to market by pursuing conditions for which there are no current FDA approved treatments. • Requires smaller and less costly drug trials with greater flexibility from the Strategy FDA. • Orphan drug market exclusivity limit
Slide 5: About / Market Data
NASDAQ:LIPO Market Data About SYMBOL NASDAQ: LIPO Lipella Pharmaceuticals is a clinical-stage biotechnology company developing and Price as of 4-24-2024 $0.72 commercializing treatments for serious diseases. 52 Week Range $0.67 - $2.44 Average Volume 52 Week 1.4M Our proprietary drug delivery techno
Slide 6: Investment Highlights
NASDAQ:LIPO Investment Highlights Drug Development Drug Delivery Lead product candidate, LP-10, a 505(b)(2) drug candidate for hemorrhagic cystitis. Expected Proprietary drug delivery technology with annual revenue per patient $20,000 per drug. potential applications in bladder, urethra, oral cavity
Slide 7: Near Term Catalysts
NASDAQ:LIPO Near Term Catalysts H2 2024 H1 2025 H2 2025 • Initiating Phase 2b trial in LP- • Initiating Phase 2a clinical • Phase 2b study in 10 trial in GvHD pending LP-10 completion interim safety results in LP- • Initiating Phase 2a studies in 310 trial LP-310 • Data from LP-10 2b clinical • Clin
Slide 8: De-Risked Assets
NASDAQ:LIPO De-Risked Assets Lipella has a broad portfolio of de-risked candidates that offer increased probability of success: • LP-10: Liposomal tacrolimus has a well-known mechanism of action and has demonstrated safety and efficacy in Phase 2a studies • LP-310: Oral rinse formulation of liposoma
Slide 9: Revenue Opportunity
NASDAQ:LIPO Revenue Opportunity Hemorrhagic cystitis: ~60,000 annually Hemorrhagic cystitis is a potentially fatal disease with great unmet need and no currently approved drug treatment. It causes chronic, painful urinary inflammation and blood loss. Expected annual revenue Oral Graft-versus-Host di
Slide 10: Executive Summary
NASDAQ:LIPO Executive Summary Emerging, clinical-stage, proprietary 505(b)(2) opportunity Drug-Delivery Focused Biotech Impressive Revenue Potential Optimized for 505(b)(2) epithelial tissues $20,000 $1.2 billion annual revenue annual revenue Patented liposomal local drug delivery Lower systemic per
Slide 11: Asset Pipeline
NASDAQ:LIPO Asset Upcoming Proprietary Asset Pre-clinical IND-Enabling Phase 1 Phase 2 Phase 3 Milestones LP-10 Anticipate FPI in 2H 2024, Pipeline hemorrhagic cystitis Study Completion in 2025 LP-310 Anticipate FPI in Q3 oral lichen planus 2024, Data by YE 2024 A growing pipeline with LP-410 Antici
Slide 12: Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss
NASDAQ:LIPO Hemorrhagic Cystitis, Uncontrolled Urinary Blood Loss Hemorrhagic cystitis is a serious, life-threatening bladder damage from pelvic radiation therapy and/or bladder-toxic chemotherapy. Millions of patients are 20% of these patients An increasing US Years after receiving Hemorrhagic cyst
Slide 13: LP-10 for Hemorrhagic Cystitis
NASDAQ:LIPO LP-10 for Hemorrhagic Cystitis Liposomal tacrolimus treatment for hemorrhagic cystitis Potent vasoconstrictor; reduces capillary blood flow to the bladder lumen Sterile powder Potent anti-inflammatory; inhibits cytokine Easy to deliver cascade and reduces injury to the bladder tissue Low
Slide 14: LP-10: Phase 2a Trial
NASDAQ:LIPO LP-10: Phase 2a Trial A Phase 2a clinical trial (NCT01393223): Top line results Next Steps • All subjects tolerated LP-10 • Multi-center, dose-escalation • Initiating Phase 2b trial in LP-10 instillations with no serious adverse study in 2H 2024 events (SAE) reported • 13 subjects with m
Slide 15: LP-10 Phase 2b Trial Design
NASDAQ:LIPO LP-10 Phase 2b Trial Design Key criteria: Randomized, double-blind, placebo controlled , multi-center clinical trial of 36 Male and Female hemorrhagic cystitis patients, randomized 1:1:1 Subjects will be randomized into one of three groups: 2mg LP-10 , 4 mg LP-10 or Placebo Primary Effic
Slide 16: LP-310 for Oral Lichen Planus
NASDAQ:LIPO LP-310 for Oral Lichen Planus Oral Lichen Planus (OLP) is a chronic inflammatory, T-cell-mediated autoimmune oral mucosal disease • Painful and comes with the risk of complications including infections, scarring, stress and depression. • Has malignant potential. • Most currently availabl
Slide 17: LP-410 for Oral Graft-Versus-Host Disease
NASDAQ:LIPO LP-410 for Oral Graft-Versus-Host Disease Oral Graft-Versus-Host Disease (GVHD) is a clinical syndrome where donor-derived immunocompetent T cells react against patient tissues directly or through exaggerated inflammatory responses following HCT. • GVHD is a major cause of morbidity and
Slide 18: LP-50 for Bladder Cancer
NASDAQ:LIPO LP-50 for Bladder Cancer Novel liposomal formulation of checkpoint inhibitors • Intravesical formulation for local, intravesical PD-1 (i.e. checkpoint) inhibition, intended for the treatment of non-muscle invasive bladder cancer (NMIBC). • Intravesical immunotherapy presents a promising
Slide 19: Manufacturing Capabilities
NASDAQ:LIPO Manufacturing Capabilities • Lipella maintains a sterile manufacturing facility in Pittsburgh, PA for the production of clinical supplies and research products. • LP-10 has been produced at high quantities in this facility for Lipella's clinical trials. • The facility is also used for de
Slide 20: Experienced Management Team
NASDAQ:LIPO Experienced Management Team Lipella is led by an experienced team with complementary skillset and years of experience working together. Jonathan Kaufman, PhD Michael Chancellor, MD Chief Executive Officer Chief Medical Officer • 23+ Years Experience • 30+ Years Experience • Co-founded Li
Slide 21: Key Takeaways
NASDAQ:LIPO Key Takeaways Drug Development Drug Delivery Broad portfolio of three promising IND-approved assets: LP-10, a 505(b)(2) drug Proprietary drug delivery technology candidate for hemorrhagic cystitis, LP-310 in oral lichen planus (OLP) and LP-410 in oral with potential applications in bladd
Slide 22: A Clinical Stage Biotechnology Company Addressing Serious Diseases
A Clinical Stage Biotechnology Company Addressing Serious Diseases with NASDAQ:LIPO Significant Unmet Need Lipella Pharmaceuticals Inc. 7800 Susquehanna Street, Suite 505 Pittsburgh, PA 15208 412-894-1853 lipellapharmaceuticals.com
Lipella Pharmaceuticals — Investor Presentation (July 2024) on 6ix